The company achieved a record monthly sales total of AU$10.1 million

PolyNovo Limited (ASX: PNV) achieved record monthly sales of AU$10.1million in November 2024, driven by strong growth in the U.S. Group revenue, including BARDA, reached AU$11.0million for the month, with YTD revenue of AU$49.6million, a 25.4% increase on STLY.

The company continues to disrupt markets, gaining leadership in full-thickness burns in the UK and Germany and expanding into oncological excisions and surgical dermatology. NovoSorb MTX adoption is accelerating in the U.S., contributing to over 62,000 patients treated globally. CEO Swami Raote praised the efforts of clinicians, partners, and employees, emphasizing the company’s impact in 46 countries, including humanitarian efforts, as NovoSorb emerges as a preferred platform in reconstructive surgery.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com